(NVO) Novo Nordisk - Ratings and Ratios
Diabetes, Obesity, Insulin, Hormone, RareDisease
NVO EPS (Earnings per Share)
NVO Revenue
Description: NVO Novo Nordisk
Novo Nordisk A/S is a leading pharmaceutical company with a strong presence in the global market, operating in two main segments: Diabetes and Obesity Care, and Rare Disease. The companys product portfolio includes a range of pharmaceuticals and medical devices, such as insulin pens, growth hormone pens, and injection needles, as well as smart solutions for diabetes treatment.
The companys Diabetes and Obesity Care segment is a key growth driver, with a strong pipeline of products and a significant presence in emerging therapy areas. Novo Nordisks commitment to innovation is evident in its collaboration with Valo Health, Inc. to develop novel drug programs for cardiometabolic diseases. Additionally, the companys partnership with UNICEF to tackle childhood obesity highlights its focus on addressing significant public health issues.
From a financial perspective, Novo Nordisks key performance indicators (KPIs) are impressive, with a high Return on Equity (RoE) of 81.24% indicating strong profitability. The companys dividend yield is also attractive, making it a compelling investment opportunity for income-seeking investors. Furthermore, Novo Nordisks revenue growth has been driven by the increasing demand for its diabetes and obesity care products, with a strong presence in key markets such as North America and Europe.
To further evaluate the companys prospects, its essential to analyze its revenue breakdown by segment and geography, as well as its research and development (R&D) pipeline. With a significant R&D investment, Novo Nordisk is well-positioned to drive future growth through innovation. Key metrics to monitor include the companys sales growth, gross margin, and operating expenses as a percentage of revenue.
NVO Stock Overview
| Market Cap in USD | 246,974m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1982-01-04 |
NVO Stock Ratings
| Growth Rating | 2.46% |
| Fundamental | 89.9% |
| Dividend Rating | 65.1% |
| Return 12m vs S&P 500 | -63.6% |
| Analyst Rating | 3.50 of 5 |
NVO Dividends
| Dividend Yield 12m | 2.49% |
| Yield on Cost 5y | 5.55% |
| Annual Growth 5y | 17.34% |
| Payout Consistency | 95.5% |
| Payout Ratio | 6.8% |
NVO Growth Ratios
| Growth Correlation 3m | -83.1% |
| Growth Correlation 12m | -92.3% |
| Growth Correlation 5y | 81.9% |
| CAGR 5y | 13.17% |
| CAGR/Max DD 5y | 0.19 |
| Sharpe Ratio 12m | -0.71 |
| Alpha | -73.05 |
| Beta | 0.899 |
| Volatility | 62.85% |
| Current Volume | 9526.5k |
| Average Volume 20d | 17913.4k |
| Stop Loss | 54 (-3.8%) |
| Signal | -1.23 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (111.07b TTM) > 0 and > 6% of Revenue (6% = 18.72b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -5.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -14.37% (prev -4.03%; Δ -10.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 121.53b > Net Income 111.07b (YES >=105%, WARN >=100%) |
| Net Debt (80.83b) to EBITDA (171.27b) ratio: 0.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.42% (target <= -2.0% for YES) |
| Gross Margin 83.95% (prev 84.53%; Δ -0.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.26% (prev 69.85%; Δ 3.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.49 (EBITDA TTM 171.27b / Interest Expense TTM 8.14b) >= 6 (WARN >= 3) |
Altman Z'' 3.57
| (A) -0.09 = (Total Current Assets 162.71b - Total Current Liabilities 207.52b) / Total Assets 482.15b |
| (B) 0.34 = Retained Earnings (Balance) 164.45b / Total Assets 482.15b |
| (C) 0.37 = EBIT TTM 158.76b / Avg Total Assets 425.77b |
| (D) 0.54 = Book Value of Equity 168.07b / Total Liabilities 314.09b |
| Total Rating: 3.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.94
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.73% = 1.86 |
| 3. FCF Margin 19.87% = 4.97 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 0.58 = 2.25 |
| 6. ROIC - WACC 44.54% = 12.50 |
| 7. RoE 77.86% = 2.50 |
| 8. Rev. Trend 96.27% = 4.81 |
| 9. Rev. CAGR 20.94% = 2.50 |
| 10. EPS Trend 88.88% = 2.22 |
| 11. EPS CAGR 25.73% = 2.50 |
What is the price of NVO shares?
Over the past week, the price has changed by +1.19%, over one month by -17.76%, over three months by -17.28% and over the past year by -57.13%.
Is Novo Nordisk a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVO is around 47.08 USD . This means that NVO is currently overvalued and has a potential downside of -16.09%.
Is NVO a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.3 | 12.8% |
| Analysts Target Price | 92.5 | 64.8% |
| ValueRay Target Price | 52.7 | -6% |
Last update: 2025-08-23 05:04
NVO Fundamental Data Overview
CCE Cash And Equivalents = 18.93b DKK (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.2545
P/E Forward = 14.3678
P/S = 0.7917
P/B = 9.4001
P/EG = 1.6367
Beta = 0.274
Revenue TTM = 311.94b DKK
EBIT TTM = 158.76b DKK
EBITDA TTM = 171.27b DKK
Long Term Debt = 87.31b DKK (from longTermDebt, last quarter)
Short Term Debt = 11.96b DKK (from shortTermDebt, last quarter)
Debt = 99.27b DKK (Calculated: Short Term 11.96b + Long Term 87.31b)
Net Debt = 80.83b DKK (from netDebt column, last quarter)
Enterprise Value = 1663.31b DKK (1582.98b + Debt 99.27b - CCE 18.93b)
Interest Coverage Ratio = 19.49 (Ebit TTM 158.76b / Interest Expense TTM 8.14b)
FCF Yield = 3.73% (FCF TTM 61.99b / Enterprise Value 1663.31b)
FCF Margin = 19.87% (FCF TTM 61.99b / Revenue TTM 311.94b)
Net Margin = 35.61% (Net Income TTM 111.07b / Revenue TTM 311.94b)
Gross Margin = 83.95% ((Revenue TTM 311.94b - Cost of Revenue TTM 50.07b) / Revenue TTM)
Tobins Q-Ratio = 9.90 (Enterprise Value 1663.31b / Book Value Of Equity 168.07b)
Interest Expense / Debt = 4.99% (Interest Expense 4.96b / Debt 99.27b)
Taxrate = 20.60% (from yearly Income Tax Expense: 26.20b / 127.19b)
NOPAT = 126.05b (EBIT 158.76b * (1 - 20.60%))
Current Ratio = 0.78 (Total Current Assets 162.71b / Total Current Liabilities 207.52b)
Debt / Equity = 0.59 (Debt 99.27b / last Quarter total Stockholder Equity 168.07b)
Debt / EBITDA = 0.58 (Net Debt 80.83b / EBITDA 171.27b)
Debt / FCF = 1.60 (Debt 99.27b / FCF TTM 61.99b)
Total Stockholder Equity = 142.65b (last 4 quarters mean)
RoA = 23.04% (Net Income 111.07b, Total Assets 482.15b )
RoE = 77.86% (Net Income TTM 111.07b / Total Stockholder Equity 142.65b)
RoCE = 69.04% (Ebit 158.76b / (Equity 142.65b + L.T.Debt 87.31b))
RoIC = 53.55% (NOPAT 126.05b / Invested Capital 235.40b)
WACC = 9.01% (E(1582.98b)/V(1682.25b) * Re(9.33%)) + (D(99.27b)/V(1682.25b) * Rd(4.99%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -100.0 | Cagr: -0.74%
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.21% ; FCFE base≈63.60b ; Y1≈69.73b ; Y5≈88.93b
Fair Price DCF = 365.6 (DCF Value 1231.68b / Shares Outstanding 3.37b; 5y FCF grow 11.02% → 3.0% )
Revenue Correlation: 96.27 | Revenue CAGR: 20.94%
Rev Growth-of-Growth: -6.86
EPS Correlation: 88.88 | EPS CAGR: 25.73%
EPS Growth-of-Growth: -12.97
Additional Sources for NVO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle